Advanced AI and ML frameworks for transforming drug discovery and optimization: With innovative insights in polypharmacology, drug repurposing, combination therapy and nanomedicine

被引:16
作者
Ambreen, Subiya [1 ]
Umar, Mohammad [1 ]
Noor, Aaisha [1 ]
Jain, Himangini [1 ]
Ali, Ruhi [1 ]
机构
[1] DPSRU, Delhi Inst Pharmaceut Sci & Res DIPSAR, Dept Pharmaceut Chem, New Delhi 110017, India
关键词
PROTEIN INTERACTION PREDICTION; LARGE-SCALE PREDICTION; X RECEPTOR ACTIVATORS; DEEP NEURAL-NETWORKS; ARTIFICIAL-INTELLIGENCE; PHYSICAL-PROPERTIES; DATABASE; DESIGN; FUTURE; QSAR;
D O I
10.1016/j.ejmech.2024.117164
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Artificial Intelligence (AI) and Machine Learning (ML) are transforming drug discovery by overcoming traditional challenges like high costs, time-consuming, and frequent failures. AI-driven approaches streamline key phases, including target identification, lead optimization, de novo drug design, and drug repurposing. Frameworks such as deep neural networks (DNNs), convolutional neural networks (CNNs), and deep reinforcement learning (DRL) models have shown promise in identifying drug targets, optimizing delivery systems, and accelerating drug repurposing. Generative adversarial networks (GANs) and variational autoencoders (VAEs) aid de novo drug design by creating novel drug-like compounds with desired properties. Case studies, such as DDR1 kinase inhibitors designed using generative models and CDK20 inhibitors developed via structure-based methods, highlight AI's ability to produce highly specific therapeutics. Models like SNF-CVAE and DeepDR further advance drug repurposing by uncovering new therapeutic applications for existing drugs. Advanced ML algorithms enhance precision in predicting drug efficacy, toxicity, and ADME-Tox properties, reducing development costs and improving drug-target interactions. AI also supports polypharmacology by optimizing multi-target drug interactions and enhances combination therapy through predictions of drug synergies and antagonisms. In nanomedicine, AI models like CURATE.AI and the Hartung algorithm optimize personalized treatments by predicting toxicological risks and real-time dosing adjustments with high accuracy. Despite its potential, challenges like data quality, model interpretability, and ethical concerns must be addressed. High-quality datasets, transparent models, and unbiased algorithms are essential for reliable AI applications. As AI continues to evolve, it is poised to revolutionize drug discovery and personalized medicine, advancing therapeutic development and patient care.
引用
收藏
页数:22
相关论文
共 303 条
[91]   A systematic approach to identify novel cancer drug targets using machine learning, inhibitor design and high-throughput screening [J].
Jeon, Jouhyun ;
Nim, Satra ;
Teyra, Joan ;
Datti, Alessandro ;
Wrana, Jeffrey L. ;
Sidhu, Sachdev S. ;
Moffat, Jason ;
Kim, Philip M. .
GENOME MEDICINE, 2014, 6
[92]   Amalgamation of 3D structure and sequence information for protein-protein interaction prediction [J].
Jha, Kanchan ;
Saha, Sriparna .
SCIENTIFIC REPORTS, 2020, 10 (01)
[93]   Deep graph embedding for prioritizing synergistic anticancer drug combinations [J].
Jiang, Peiran ;
Huang, Shujun ;
Fu, Zhenyuan ;
Sun, Zexuan ;
Lakowski, Ted M. ;
Hu, Pingzhao .
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2020, 18 :427-438
[94]  
Jiang T, 2020, BEHAV THER, V51, P675, DOI 10.1016/j.beth.2020.05.002
[95]   KDEEP: Protein-Ligand Absolute Binding Affinity Prediction via 3D-Convolutional Neural Networks [J].
Jimenez, Jose ;
Skalic, Miha ;
Martinez-Rosell, Gerard ;
De Fabritiis, Gianni .
JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2018, 58 (02) :287-296
[96]  
John I., 2018, ICLR 2019 C
[97]   A review of the applications of data mining and machine learning for the prediction of biomedical properties of nanoparticles [J].
Jones, David E. ;
Ghandehari, Hamidreza ;
Facelli, Julio C. .
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, 2016, 132 :93-103
[98]   Artificial Intelligence in Drug Design-The Storm Before the Calm? [J].
Jordan, Allan M. .
ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (12) :1150-1152
[99]   Leveraging multi-way interactions for systematic prediction of pre-clinical drug combination effects [J].
Julkunen, Heli ;
Cichonska, Anna ;
Gautam, Prson ;
Szedmak, Sandor ;
Douat, Jane ;
Pahikkala, Tapio ;
Aittokallio, Tero ;
Rousu, Juho .
NATURE COMMUNICATIONS, 2020, 11 (01)
[100]   druGAN: An Advanced Generative Adversarial Autoencoder Model for de Novo Generation of New Molecules with Desired Molecular Properties in Silico [J].
Kadurin, Artur ;
Nikolenko, Sergey ;
Khrabrov, Kuzma ;
Aliper, Alex ;
Zhavoronkov, Alex .
MOLECULAR PHARMACEUTICS, 2017, 14 (09) :3098-3104